Background: Family history is a well recognized risk factor for breast cancer, but its impact in terms of breast cancer survival is uncertain. The recent identification of breast cancer predisposing genes has provided new clinical insights in this field.
Introduction
Family history of breast cancer is an established risk factor for the development of the disease [1] . Five to ten percent of breast cancer cases are hereditary and germline mutations in the breast cancer predisposing genes BRCA1 and BRCA2 may account for 80% of the hereditary cases [2] . It is unclear whether the prognosis of hereditary breast cancer differs from that of sporadic cases. In hereditary non polyposis colorectal cancer, patients with constitutional mutations in the MLH1 or MSH2 genes have been found to have a better prognosis than those without mutations [3, 4] . Whether or not the same survival advantage is true for hereditary breast cancer is unclear. Pathological features suggest that there may be underlying differences in familial/hereditary breast cancer compared to sporadic cases. BRCA1-tumors are more often poorly differentiated, highly proliferating tumors, with a high frequency of estrogen receptor negativity, and a higher rate of p53 mutations [5] [6] [7] . Nevertheless, BRCA1 -associated tumors also demonstrate intratumoral infiltrating lymphocytes, an increased proportion of medullary histological type, less frequent node involvement, a relatively low HER2/cerbB-2/neu overexpression, and a decreased angiogenesis [8] [9] [10] . Distinct somatic genetic changes have been preliminary reported in hereditary cases compared to sporadic breast carcinoma [11] . Somatic mutations in BRCA1 or BRCA2 are extremely rare in sporadic breast cancer, but the expression of BRCA1 may be decreased in some cases [12] .
Survival studies may reveal further information on the biological differences between hereditary and sporadic tumors. Survival information is essential for the elaboration of preventive and therapeutic strategies, and for counseling women at increased risk of breast cancer.
Studies looking at differences in survival between familial/hereditary and sporadic cases of breast cancer can be grouped into three study categories: family historybased, linkage-based, and mutation-based. Family history-based studies were particularly useful prior to the localization of the BRCA1 and BRCA2 genes. However, the definition of hereditary breast cancer has not been clearly established. Moreover, not all women with a family history of breast cancer have BRCA IIBRCA2 mutations, and not all BRCA1IBRCA2 affected carriers 13] , studies comparing the survival in mutation carriers compared to controls were started. Results of these studies have been conflicting. This paper offers a review of the literature in an attempt to answer the question of whether hereditary factors influence prognosis in breast cancer.
Design
English literature identified through Medline between 1976 and February 1999 was reviewed including the following search terms: breast cancer, survival, prognosis, family history, genetics, BRCA1, BRCA2, and related articles. We included thirty-one studies providing information on the association between either family history of breast cancer, linkage to BRCA1IBRCA2, or germline mutations in BRCA1IBRCA2, and the prognosis of breast cancer. (Table 1) In the absence of an established epidemiological definition of familial or hereditary breast cancer, the studies can be separated in early-onset breast cancer analyses, case-control population-based studies and studies undertook in the context of referral or cancer clinics.
Results

Family history-based studies
Three studies evaluated the influence of a family history of breast cancer in early-onset cases [14] [15] [16] . All three have less than one hundred cases and only one [16] demonstrated a better survival for the affected women with a positive family history. The latter study included nine cases from breast/ovarian cancer families and there was significantly more node negative breast cancer in the cases than in the control group.
Three studies can be considered as case-control population-based [17] [18] [19] . In a large study based on the population database and cancer registry of the Utah state, a worse prognosis was significantly associated with family history, but only in the sub-group of premenopausal women [18] . Malone et al. demonstrated a better prognosis for early onset cases with a positive family history [19] .
Twelve studies investigated the prognostic impact of family history in the context of breast cancer seen in referral or cancer clinics [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] . Among these, only five described selection criteria for cases [21, [28] [29] [30] [31] . Two studies found a better prognosis in association with a positive family history [21, 26] . Notably, the study by Albano et al. [21] was restricted to hereditary breast cancer syndrome. A worse outcome, in post-menopausal patients only, was associated with first degree relatives affected by breast cancer in one study [29] . In this study, family history was an independent prognostic factor in multivariate analysis despite a short follow-up and a sixteen year period of time over which cases were collected. Lees et al. [25] concluded, after stratification by stage, that the presence of a positive family history (defined as any relative affected by breast cancer) was associated with a worse outcome, but family history was not a significant prognostic factor in multivariate analysis. The eight other studies with often larger number of cases concluded to the absence of a significant impact on the prognosis of the family history [20, 22-24, 27, 28, 30, 31] .
The worse prognosis usually associated with very early-onset breast cancer (^35 years) seems not to be influenced by family history.
Linkage-based studies ( Table 2) In two of the three linkage-based studies, linked cases were found to have a better prognosis than did controls [32, 33] . Porter et al. [32] studied thirty-five breast cancer patients from eight BRCA 1-linked families, and showed an 83% five year survival. The survival for age-matched controls was 61%. Similarly, Marcus et al. [33] reported a five-year survival of 67% in BRCAl-linked cases and Abbreviations: AJ -Ashkenazi Jewish; BC -breast cancer; DCIS -ductal carcinoma in situ; FH -family history; F -first; S -second; DR -degree relative; mut. -mutation; NS -not significant (at 5% level); n/s -not stated; O -ovarian; OS -overall survival; DFS -disease-free survival. * 56% vs. 71% when probands excluded (P = 0.21).
63% in the BRCA2 /other gene-linked group, compared to 59% in controls. However, after correcting for age and stage, the adjusted crude death hazards ratio for BRCAl-and BRCA2/other gene-linked cases was 1.65 (P = 0.12) and 1.43 (P = 0.18), respectively. The third linkage based study looked at forty-two BRCA2-linked breast cancer patients from five families in Iceland [34] . The 10-year overall survival was 45% in cases, compared to 65% in controls (P < 0.05). (Table 3) There are 10 mutation-based studies [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] . These can be divided into four categories based on the study population selected. Three papers reported studies from a broad population of women with BRCAl mutations [38, 40, 42] , three studies looked at specific founder BRCAl IBRCA2 mutations in Ashkenazi Jewish women [35, 41, 44] , two studies reflected the experience of referral cancer clinics [39, 43] , one study selected BRCAl germ-line mutation carriers with early onset-breast cancer [37] , and one study reported results from the single BRCA2 germline mutation identified in Iceland [36] . Of the three studies screening for specific Ashkenazi Jewish BRCA1IBRCA2 germline mutations, one showed a significantly worse survival in mutation carriers [35] whereas the other two studies showed no survival difference between carriers and non-carriers [41, 44] . When early onset-breast cancer patients with BRCA1 mutations were selected as the cases, a worse five-year overall survival was seen in the germline mutation carrier group [37] . No significant difference in survival between cases and controls was shown in the six other studies [36, [38] [39] [40] 42, 43] .
Mutation-based studies
Discussion
Family history-based studies
Family history is an instructive source of information in medicine. The validity of the familial history in oncology, either reported by the patients themselves or obtained through a population-based cancer registry, has been well recognized [45, 46] . Positive family history is a function of the number of relatives, the background risk and the etiologic heterogeneity of the disease, and the age distribution of relatives. In population-based casecontrol studies, no adjustment are usually made for family size (number of relatives) or characteristics of the relative (mean age, sex, age-specific risks). Therefore, a family history report cannot give stable or consistent estimations from one study to another because of variations in familial variables (size and age distribution from one population to another). This is responsible of bias in using family history as a risk factor in case-control studies [47] . Constructing two historical cohorts of the relatives of cases and the relatives of controls, and comparing cumulative incidence of cancer in these two cohorts can avoid some of these problems [44, 48] .
Positive first degree family history is recorded in 10%-20% of the affected women with breast cancer and family history of breast cancer has been used to identify women at high cancer risk for genetic studies. In the absence of a strict definition of familial breast cancer and hereditary breast cancer syndromes, these family history-based studies are heterogeneous studies according to their criteria for a positive family history. So family history-based studies have the disadvantage of grouping true hereditary cases with those of familial clustering. These studies also markedly vary by how (in-person interview, chart review) and when they have assessed it. Family history noted at time of diagnosis for early-onset cases cannot be easily compared to family history collected in an age-unrestricted study, simply because, by definition, their relatives will be younger.
Population-based studies would give an a priori more precise appraisal of the outcome in a defined population, compared to the evaluation of cases recruited through referral centers.
A crucial issue is the definition of an adequate control group. Ideally, cases should be at least matched for age, stage and year of diagnosis to allow some comparisons. As some studies spanned over some years or collected cases in the 1960s, control groups have to be appropriate, otherwise it would not take in account potential differences in diagnosis and treatment of breast cancer over time. In other respects, lead-time bias may result from the knowledge of family history, resulting in a diagnosis of breast cancer at an earlier stage because of screening procedures actively followed. None of the studies mentioned the importance of ethnicity-matching for controls, which may be relevant as some publications strongly suggested an outcome difference linked to ethnic origins [49, 50] . These numerous methodological biases encountered in family history-based studies are probably responsible for the discrepancies noted in the impact of family history as a prognostic factor.
Linkage-based studies
The interpretation of linkage-based studies is problematic. There are sources of bias inherent in the study design, and additional confounders exist in each study. In the study by Porter et al. [32] , differences in stage were not taken into account. Secondly, cases and controls were not matched for date of diagnosis, cases being diagnosed from 1942-1992, while controls were diagnosed between 1971-1973. As such, treatment may have differed. Support this possibility, the five-year survival rate in the control group was 59% which is lower than one would expect now. Also, four families in the study have a probability of linkage of less than 95%. A sporadic early-onset breast cancer case in a family investigated by linkage analysis can result in a negative lod score. In fact, some families with negative lod scores at the BRCA1 locus, actually do carry a BRCA1 germline mutation [51] . In the study of Marcus et al. [33] , only 51% of cases were evaluated for survival and they were diagnosed at a younger age than were controls (average age of 42.8 years in cases versus 62.9 years in controls). In addition, there were more stage I and II tumors in the linked groups. It is therefore of interest that after adjusting for age and stage, there was a non significant trend toward worse survival in the linked groups (P -0.12 for #RG4i-linked, P -0.18 for BRCA2/other gene-linked). In a preliminary report from Icelandic women with breast cancer, 2?/?G42-linked cases had a worse survival than did controls [34] . Linkage to BRCA2 was an independent prognostic variable in multivariate analysis. However, this study is based on a small number of individuals from a population with only one common BRCA2 mutation (999del5), and therefore results may not be generalisable. Moreover, a more recent study of this Icelandic BRCA2 mutation in the same population demonstrated no difference in survival, when the control group was matched for age and year of diagnosis [36] .
This probably reflects the impact of the improvement in the management and diagnosis of breast cancer during the last decades. Difficulties in linkage-based studies include the fact that they generally contain rather small numbers of living individuals. Families included are those in which several individuals have breast cancer, raising awareness, and potentially leading to screening and lead time bias. Ascertainment bias is also an issue, as inevitably, living cases are preferentially included in the studies. Interestingly, an increased risk for breast cancer associated with recent birth cohort in BRCA1 mutation carriers has been reported [52] . Therefore, results implying improved survival in the linked group must be interpreted with caution.
Mutation-based studies
Several sources of bias exist in mutation-based studies. Ascertainment bias is an issue in many, as living affected women are preferentially offered testing [41] . Verhoog et al. [42] attempted to correct for this by analyzing the data with the exclusion of the nine affected probands. This resulted in a non-significant trend toward a higher death and recurrence rate in BRCA1 -mutation carriers. However, exclusion of the proband does not adequately correct for ascertainment bias [53] . The likelihood for a patient affected with breast cancer to be ascertained also depends of the structure of the pedigree (e.g., small families, predominance of males, deceased relatives), and the knowledge of the family history. Foulkes et al. [35] eliminated survivor bias with their study design, as mutation status was studied from paraffin blocks regardless of whether or not the patient was living. In this study, a worse survival was seen in BRCA 1 -mutation carriers (five-year survival: cases 64.3%, controls 97.5%; P -0.002). However, in this study, as in the study by Robson et al. [41] , only Ashkenazi Jewish women were selected. It may be that different BRCA1 mutations confer a different prognosis, and the results demonstrated in founder populations as seen in the South Sweden [40] , in the Ashkenazim [35, 41, 44] , or the Icelandic population [36] may not apply to other populations.
The absence of prognostic significance of BRCA mutations in a Ashkenazi Jewish community-based survey has been recently reported [44] . This interesting study evaluated the survival of breast cancer-affected first degree relatives of Ashkenazi Jewish mutation carriers compared to breast cancer cases diagnosed in first degree relatives of non-carriers. Even with an adjustment for age and period of diagnosis, this study has limitations because of the absence of ascertainment of cases or cause of death, of adjustment for stage of the disease, and of mutation screening in cases and controls.
Determining the overall survival of the BRCA -affected carriers is not an accurate measure of their survival from breast cancer, as they could die from other BRCA -related tumors. In Johannsson study [40] four of the patients with both breast and ovarian cancer died of ovarian cancer.
Non-exclusion of patients with in situ breast carcinoma might influence the survival evaluation [41] .
Another point to be noted in several of the mutation studies is the inclusion of patients with missense mutations [39, 43] . Many of these mutations are of unknown biological significance, and including them in the case group may have confounded the results. In addition, in most of the studies, the BRCA I /BRCA 2 genes were not sequenced in the control group. As such, the presence of mutations in this group cannot be ruled out. However, in the studies by Foulkes et al. [35] and by Robson et al. [41] , the cases and controls were all tested for the same three mutations commonly found in the Ashkenazi Jewish population. Finally, all of the mutation-based studies have a small sample size, making the play of chance more likely to be a problem than in larger studies, and the control group may not be appropriate in all studies, e.g., not adequately staged-matched. The study designed of Ansquer et al. [37] is attractive, as it was based on a prospective follow-up with the same mutation screening in cases and controls, but for reliable results, this kind of approach requires a multicentre recruitment of cases and many years of follow-up. A retrospective cohort design using populations with founder mutations, and mutation analysis of archived tissue, may be able to achieve similar results in a shorter time.
Perspectives and conclusion
Some of the discrepancies in the outcome attributed to familial or hereditary breast cancer noted through these heterogeneous studies may be explained by methodological issues. It is not clear that further prognostic studies based solely on family history will be able to completely resolve these problems. Moreover, as molecular analysis of BRCAJ and BRCA2 is now available, using family history as a surrogate for mutation status in casecontrol population-based studies of breast cancer is no longer justified. Linkage studies, because of their inherent biases, should be restricted to use as a research tool to confirm or exclude chromosomal regions to be investigated, or interpreted with extreme caution.
A strongly positive family history of breast cancer is not always associated with mutations in BRCA1 or BRCA2. This is partly attributable to technical limitations, but also because of the assumed existence of other susceptibility gene(s). The reverse situation is also true. Among the one hundred twenty carriers of any of the three founder BRCA1IBRCA2 Askhenazi Jewish mutations identified by Struewing et al. in a population-based designed study [54] , thirty-one (26%) did not report a family history of breast or ovarian cancer among firstor second-degree relatives. In a population-based study of breast cancer occurring before age forty years [55] , 7 out of 10 (70%) of the BRCA1 mutation carriers and 4 out of 9 (44%) of the BRCA2 mutation carriers had no history of breast cancer in a first-or second-degree relative. Thus, family history is not a very sensitive parameter of the existence of constitutional BRCA11 BRCA2 mutations.
Because of imperfect molecular assays, small number of patients studied and an insufficient follow-up time, we cannot yet conclude on the precise impact of the breast cancer predisposing genes on the outcome of affected women. Nevertheless, no studies have showed a survival advantage for mutation carriers. This seems to indicate that BRCAl-rdated breast cancer is not associated with a survival advantage, and that in fact, certain BRCA1 germline mutations confer a worse prognosis. However, to adequately answer this question, we need more efficient molecular tools to identify all the genetic changes responsible for breast cancer predisposition, and large prospective studies or well designed retrospective analyses, to evaluate their clinical consequences. These future studies will also provide essential insights into this heterogeneous disease, such as a better understanding of genotype-phenotype correlations, the identification of modifier genes and relevant environmental factors, and a more complete appreciation of the tumorigenic process involved in familial and hereditary breast cancer [56] . The absence of somatic mutations of BRCA1I BRCA2 in the majority of sporadic breast cancer favors the hypothesis of a different carcinogenic mechanism in hereditary cases, which may ultimately be evident in the outcome evaluation.
An accurate appraisal of the survival according to the familial or genetic status is essential for counseling at risk individuals or breast cancer gene carriers. The prognosis for BRCA mutation-related tumors is important, because this knowledge may influence the management of women at risk, by predicting the overall benefit of preventive measures [57, 58] . Finally, a thorough understanding of the biological functions of BRCA 1 and BRCA2, and their respective influence on the response to radiation or chemotherapy, may also help in the design of the optimal treatment of breast cancer developing in BRCA mutation carriers.
